Credit Suisse AG Has $59.69 Million Position in ABIOMED, Inc. (ABMD)

Credit Suisse AG increased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 28.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 132,724 shares of the medical equipment provider’s stock after buying an additional 29,503 shares during the quarter. Credit Suisse AG owned about 0.29% of ABIOMED worth $59,693,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. BlackRock Inc. grew its stake in shares of ABIOMED by 10.3% in the third quarter. BlackRock Inc. now owns 3,117,569 shares of the medical equipment provider’s stock valued at $1,402,127,000 after buying an additional 290,298 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of ABIOMED by 35.0% in the second quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock valued at $634,610,000 after buying an additional 401,800 shares in the last quarter. FMR LLC grew its stake in shares of ABIOMED by 34.2% in the second quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock valued at $282,988,000 after buying an additional 176,394 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd grew its stake in shares of ABIOMED by 1,030.0% in the third quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock valued at $287,325,000 after buying an additional 582,318 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of ABIOMED by 90.1% in the third quarter. Janus Henderson Group PLC now owns 517,612 shares of the medical equipment provider’s stock valued at $232,797,000 after buying an additional 245,286 shares in the last quarter. Institutional investors own 84.88% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. ValuEngine cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. BidaskClub cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Thursday, November 15th. BTIG Research raised ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective for the company in a research note on Friday, November 2nd. Morgan Stanley raised ABIOMED from an “equal” rating to a “weight” rating and lifted their price objective for the company from $396.00 to $496.00 in a research note on Wednesday, November 7th. Finally, Zacks Investment Research cut ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, July 31st. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $402.78.

In other news, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the completion of the transaction, the vice president now directly owns 48,954 shares of the company’s stock, valued at approximately $21,172,605. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Andrew J. Greenfield sold 4,440 shares of the company’s stock in a transaction dated Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total value of $1,753,800.00. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.

ABMD opened at $299.41 on Monday. ABIOMED, Inc. has a 12 month low of $186.72 and a 12 month high of $459.75. The firm has a market cap of $13.49 billion, a P/E ratio of 96.90, a P/E/G ratio of 2.45 and a beta of 0.35.

ABIOMED (NASDAQ:ABMD) last released its earnings results on Thursday, November 1st. The medical equipment provider reported $1.09 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.36. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The firm had revenue of $181.78 million during the quarter, compared to analysts’ expectations of $175.41 million. During the same period in the previous year, the firm posted $0.54 EPS. ABIOMED’s revenue for the quarter was up 36.9% on a year-over-year basis. Analysts anticipate that ABIOMED, Inc. will post 3.57 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.wkrb13.com/2018/11/26/credit-suisse-ag-has-59-69-million-position-in-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Further Reading: Can systematic risk be avoided?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply